[Diovan efficacy and tolerance in mild and moderate hypertension].
OBJECTIVE
To study clinical effectiveness and tolerance of diovan, a new angiotensin-II antagonist, in patients with mild and moderate blood hypertension (BH).


METHODS
The trial included 20 patients (13 males and 7 females) aged 35-60 years with mild and moderate BH. All the patients received diovan (valsartan) for 8 weeks in a dose 80 mg/day. If the hypotensive effect was inadequate, the dose was increased to 160 mg/day.


RESULTS
2-week treatment with diovan brought a significant fall of both systolic and diastolic blood pressure. In 8 weeks the hypotensive effect enhanced. Lowering of diastolic BP to 90 mm Hg or at least by 10% was achieved in 90% of the patients. Tolerance was good, unfavorable metabolic shifts were absent.


CONCLUSIONS
Diovan proved to be effective and safe in therapy of patients with mild and moderate BH.
Zakirova
A N
AN
Zakirova
N E
NE
D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004342:Drug Hypersensitivity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012449:Safety; D012720:Severity of Illness Index; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D000959:Antihypertensive Agents; D013777:Tetrazoles; D000804:Angiotensin II; D000068756:Valsartan; D014633:Valine